Can-Fite Secures Key Japanese Patent for Obesity Drug Namodenoson
Event summary
- Can-Fite BioPharma received Japanese patent allowance for Namodenoson's anti-obesity technology on June 26, 2026.
- The patent covers A3 adenosine receptor agonists for fat loss and obesity treatment.
- This strengthens Can-Fite's global IP portfolio, adding to existing protections in the US, Canada, Australia, and Israel.
- Namodenoson is an orally administered drug with a differentiated mechanism targeting adipogenesis and metabolic regulation.
The big picture
The Japanese patent strengthens Can-Fite's global IP strategy as it targets the rapidly expanding obesity therapeutics market, projected to exceed $60 billion by 2030. The approval comes amid growing demand for safe, effective oral therapies, positioning Namodenoson against competitors like GLP-1 receptor agonists. This move underscores Can-Fite's push into metabolic diseases alongside its existing oncology pipeline.
What we're watching
- Market Differentiation
- Whether Namodenoson's oral administration and safety profile can position it as a viable alternative to existing obesity therapies.
- Partnership Potential
- The pace at which Can-Fite can leverage this patent for strategic collaborations in Japan's pharmaceutical market.
- Clinical Validation
- How upcoming clinical data will support Namodenoson's anti-obesity claims and drive commercial adoption.
Related topics